Please ensure Javascript is enabled for purposes of website accessibility

Reckitt Benckiser Group Reveals Sales Up 7%

By Mark Rogers - Apr 22, 2013 at 4:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Reckitt Benckiser Group Plc issues its first-quarter results.

LONDON -- The shares of Reckitt Benckiser (RKT 1.17%) (RBGP.F -5.28%) climbed 1% to 4,755 pence during early London trade this morning after the consumer-products giant revealed first-quarter sales of 2.5 billion pounds.

Reckitt said the sales figure was 7% higher than last year and was driven by a strong emerging-market performance and "higher incidences of cold and flu in the U.S."

Reckitt's Health division, which makes cold-remedy products such as Strepsils, Nurofen and Mucinex, enjoyed revenue growth of 5% in North America and Europe. The division's revenue grew 13% like-for-like, and now account for 27% of group sales.

Reckitt's recent emphasis on emerging markets continues, with Latin America, Asia, and Pacific revenues growing by 11%, as the group continues to roll out its "powerbrands" such as Durex and Gaviscon in India, Brazil, and China.

The company's largest division, Hygiene, grew like-for-like sales by 9%, reflecting the group's overall strong first-quarter results.

Commenting on the results, chief executive Rakesh Kapoor added:

We are pleased with a strong start to the year, with our Health and Hygiene brands leading RB's growth across all geographies. Growth was driven from a combination of innovations, increased Brand Equity Investments and better in market execution.

On Suboxone, our patient-preferred sublingual film in the U.S. increased its market share to 69%. The generic version of tablets became available during March, and their early impact is in line with expectations.

We expect continued challenging market conditions but nonetheless we remain confident that we can achieve our full year targets of 5-6% total net revenue growth while maintaining operating margins.

With a market cap of 34 billion pounds, Reckitt trades at around 18 times expected earnings and on a prospective dividend yield of 3%.

Of course, whether today's results, the current share price, and the emerging-market prospects combine to make Reckitt Benckiser a buy is something only you can decide.

But if you already own Reckitt shares and are interested in other high-quality companies with growth opportunities, this exclusive wealth report reviews five particularly attractive blue chips that have been compiled carefully by The Motley Fool's expert stock pickers.

Indeed, all five opportunities offer a mix of robust prospects, illustrious histories, and dependable dividends, and have just been declared by the Fool "5 Shares You Can Retire On"!

Just click here for the report -- it's free.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Reckitt Benckiser Group plc Stock Quote
Reckitt Benckiser Group plc
$6,222.00 (1.17%) $72.00
Reckitt Benckiser Group plc Stock Quote
Reckitt Benckiser Group plc
$75.01 (-5.28%) $-4.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.